                         SEQUENCE LISTING

<110>  QuantBioRes A/S
 
<120>  Covid-19 blocking peptide

<130>  P5869PC00

<160>  6     

<170>  PatentIn version 3.5

<210>  1
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(18)
<223>  CovA

<400>  1

His Arg Trp Lys Gln Trp Trp Trp Ala Gln Cys Pro Tyr Asp Lys Leu 
1               5                   10                  15      


Asp Met 
        


<210>  2
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(18)
<223>  CovB

<400>  2

Leu Trp Asp Lys Glu Arg Thr Asn Trp Asp Ala Glu Arg Arg Gly Tyr 
1               5                   10                  15      


Asp Tyr 
        


<210>  3
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(18)
<223>  CovC

<400>  3

Gln Asp Glu Trp Asp His Lys Asp Ala Pro Asp Trp Gly Arg Cys Leu 
1               5                   10                  15      


Thr Arg 
        


<210>  4
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(18)
<223>  CovD

<400>  4

Arg His Trp Phe Trp Trp Gln Gln Cys Trp Ala Arg Met Val Thr Asp 
1               5                   10                  15      


Leu Tyr 
        


<210>  5
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(18)
<223>  CovE

<400>  5

Asp Trp Asn Thr Asp Pro Lys Asp Gln Ile Cys Asp Pro His Asp Gln 
1               5                   10                  15      


Leu Gln 
        


<210>  6
<211>  18
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide


<220>
<221>  MISC_FEATURE
<222>  (1)..(18)
<223>  CovF

<400>  6

Tyr Glu Asp Gln Asn Arg Thr Leu Cys Arg Val Trp Asp Pro Lys Asp 
1               5                   10                  15      


Lys Pro 
        


